Adaptimmune Therapeutics PLC (ADAPY)
Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as famitresgene autoleucel or afami-cel), an autologous T-cell immunotherapy that employs genetically modified cells to treat adults with advanced, unresectable, or metastatic synovial sarcoma. The company is also advancing Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, currently in Phase 1 clinical trials for head and neck cancer. Additionally, Adaptimmune is developing T-cell therapies engineered to target PRAME (ADP-600) and CD70 (ADP-520). The firm engages in strategic collaborations, notably with Galapagos for a clinical proof-of-concept trial of uza-cel (ADP-5701) in head and neck cancer, leveraging Galapagos' decentralized manufacturing platform. Further partnerships include a licensing agreement with Noile-Immune Biotech, Inc. and a strategic alliance with the MD Anderson Cancer Center. Established in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Adaptimmune Therapeutics plc
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
GBAdaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom.
Its pipeline includes TECELRA (also known as famitresgene autoleucel or afami-cel), an autologous T-cell immunotherapy that employs genetically modified cells to treat adults with advanced, unresectable, or metastatic synovial sarcoma.
The company is also advancing Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, currently in Phase 1 clinical trials for head and neck cancer.
Additionally, Adaptimmune is developing T-cell therapies engineered to target PRAME (ADP-600) and CD70 (ADP-520).
The firm engages in strategic collaborations, notably with Galapagos for a clinical proof-of-concept trial of uza-cel (ADP-5701) in head and neck cancer, leveraging Galapagos' decentralized manufacturing platform. Further partnerships include a licensing agreement with Noile-Immune Biotech, Inc. and a strategic alliance with the MD Anderson Cancer Center. Established in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.
Leadership
Helen Katrina Tayton-Martin
Co-Founder
Christopher James Hill
CEO, CFO, Secretary & Director
Dana Lynch
Senior Director of Corporate Communications
Juli Miller
Vice President of Corporate Affairs & Investor Relations
Employees
--
Country
GB
Sector
Healthcare
Website
adaptimmune.com
| Name | Shares | % | Source |
|---|---|---|---|
 Bertrand William C JR Chief Operating Officer | 986.4K | -- | FORM 4 |
 Rawcliffe Adrian Chief Executive Officer, Director | 44.3K | -- | FORM 4 |
 Piccina Cintia Chief Commercial Officer | 18.4K | -- | FORM 4 |
 Lunger John Chief Patient Supply Officer | 7.5K | -- | FORM 4 |
 Norry Elliot Chief Medical Officer | 7.5K | -- | FORM 4 |
Insiders
- Bertrand William C JRChief Operating Officer
- Rawcliffe AdrianChief Executive Officer, Director
- Piccina CintiaChief Commercial Officer
- Lunger JohnChief Patient Supply Officer
- Norry ElliotChief Medical Officer
GB30d Avg
253.91K
60d Avg
210.50K
90d Avg
193.97K